Genomics-diagnostic leader MedGenome has acquired a majority stake in Green Cross Genetics Lab, aiming to expand its footprint in India’s molecular-diagnostics market and accelerate genomics-led testing across disease categories and underserved regions.
Glimpse:
Through the strategic acquisition, MedGenome gains access to Green Cross’s regional lab network and clinical partnerships, enabling faster rollout of genomic testing, integrated diagnostics and research services. The move underscores the company’s ambition to deepen its capabilities in oncology, inherited disorders and population screening, while enhancing accessibility in Tier-II/III cities.
Bengaluru-based genomics and diagnostics company MedGenome has announced the purchase of a controlling interest in Green Cross Genetics Lab, a move that significantly broadens its laboratory network and strengthens its diagnostics ecosystem. While exact financial details have not been publicly disclosed, the acquisition aligns with MedGenome’s strategy of deepening its presence in the Indian market through M&A.
Green Cross Genetics Lab brings to the table a well-established regional infrastructure, collection-centre footprint and clinician network. By combining this with MedGenome’s genomic-sequencing platforms, bioinformatic capabilities and wide test portfolio, the merged entity is positioned to deliver advanced diagnostics including hereditary-cancer panels, non-invasive prenatal testing (NIPT), liquid-biopsy assays and preventive genetic screening across a broader geographic footprint.
According to Dr Vedam Ramprasad, CEO of MedGenome, the acquisition will enable faster time-to-market for new test offerings and deeper penetration into underserved markets. He remarked that genomic medicine in India must move beyond metro centres and lab corridors into semi-urban and rural markets, and the partnership with Green Cross is a key lever in that mission.
Industry observers note that the diagnostics market in India is becoming increasingly competitive, with demand rising for genomics-driven tests and value-added services. MedGenome’s acquisition strategy addresses the need for scale, access, and integrated services lab-plus-clinic-plus-data. The challenge ahead will be integrating operations, maintaining high quality standards, and making pricing accessible while scaling.
Looking forward, the combined entity plans to expand collection centres, upgrade local labs to handle high-throughput genomic workflows, and build research collaborations to generate population-specific genomic insights. If execution succeeds, this deal may mark a new chapter in India’s diagnostics landscape one where genomics is not confined to elite hospitals but becomes a mainstream part of early-diagnosis and health-management systems.
“By bringing together our genomics-first capabilities with Green Cross’s local reach and regional infrastructure, we are accelerating access to precision diagnostics for every Indian regardless of city or income.”
By
HB Team
